This is great news. It demonstrates that GHDX has other revenue stream route beyond the traditional medical reimbursement. As more and more of these personalized medicine is developed, drug companies will have to use companies like GHDX for the dianostics to screen the efficacy of their drug. And this revenue is not subject to the government budget regulation. With this and the additional Whole Genome Expression Analysis, GHDX is no longer a one trick pony show anymore as criticized by some. Just my take.